|
Feb 21
|
Ionis Pharmaceuticals price target lowered to $60 from $61 at Raymond James
|
|
Feb 20
|
Why Ionis Pharmaceuticals (IONS) Is Among the Most Oversold Healthcare Stocks to Buy Now
|
|
Feb 20
|
Ionis' Q4 Earnings and Sales Beat Estimates, Tryngolza Launch in Focus
|
|
Feb 20
|
New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
|
|
Feb 20
|
Ionis Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
|
|
Feb 20
|
Q4 2024 Ionis Pharmaceuticals Inc Earnings Call
|
|
Feb 20
|
Ionis Pharmaceuticals Inc (IONS) Q4 2024 Earnings Call Highlights: Surpassing Revenue ...
|
|
Feb 19
|
Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales
|
|
Feb 19
|
Ionis Pharmaceuticals (IONS) Reports Q4 Earnings: What Key Metrics Have to Say
|
|
Feb 19
|
Ionis Pharmaceuticals: Q4 Earnings Snapshot
|
|
Feb 19
|
Ionis reports fourth quarter and full year 2024 financial results
|
|
Feb 18
|
Ionis Pharmaceuticals (IONS): Among Top Insider Stock Buys And Sells In January
|
|
Feb 17
|
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS
|
|
Feb 11
|
Why Insiders Are Selling Ionis Pharmaceuticals, Inc. (IONS) Recently
|
|
Oct 9
|
Ionis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge Funds
|
|
Oct 8
|
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
|
|
Sep 11
|
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
|
|
Sep 10
|
Ionis announces pricing of $500.3 million public offering
|
|
Sep 9
|
Ionis announces proposed public offering of common stock
|
|
Sep 5
|
Why Is Zoetis (ZTS) Up 1.4% Since Last Earnings Report?
|